Matthew Frigault, M.D.
Dr. Frigault is a medical oncologist in the Hematologic Malignancy Program at the Massachusetts General Hospital Cancer Center, as well as Assistant Director of the Cellular Therapy Service. In addition, he serves as an Instructor at Harvard Medical School. Dr. Frigault recently completed his oncology fellowship at the combined Massachusetts General Hospital/Dana Farber Cancer Institute training program where he worked with Dr. Marcela Maus, head of the Cellular Immunotherapy Program at Massachusetts General Hospital.
Dr. Frigault is responsible for attending on the inpatient bone marrow transplant and leukemia services, managing outpatient cellular therapy patients and overseeing the cellular therapy service in charge of the hospital’s standard of care and clinical research efforts. His current research is focused on the translational aspects of cellular therapies with the goal of developing the next generation of cellular therapies utilizing multi-cistronic lentiviral vectors, CRISPR gene editing and clinical correlatives.
Dr. Frigault’s prior research experience includes preclinical development and correlative studies relevant to T cell immunotherapy in the lab of Dr. Carl June while in graduate school at the University of Pennsylvania. During his post-graduate training at Johns Hopkins, he focused on cellular therapies utilizing marrow infiltrating lymphocytes and chimeric switch receptors in the lab of Dr. Ivan Borrelo.
Dr. Frigault received his Bachelor of Arts degree in Biology and Biological Sciences from the College of the Holy Cross, and his master’s and M.D. degrees from the University of Pennsylvania.
Alexander Gabibov, D.Sc.
Since 1997, Dr. Alexander Gabibov has been Head of the Laboratory of Biocatalysis at the Shemyakin & Ovchinnikov Institute of Bioorganic Chemistry at the RAS, and in 2000 he became Professor of Cell Biology at the Moscow State University. In 2003, Dr. Gabibov was named an Associate of the Russian Academy of Sciences, and in 2008 was appointed President of the Russian Biochemical and Molecular Biology Society.
In 2009, Dr. Gabibov took on the role of Foreign Correspondent at the National Academy of Pharmacy in France. In 2012, he was nominated as Head of Department of Industrial Pharmacology at the Lomonosov Moscow State University.
Throughout his career, Dr. Gabibov has been a prolific contributor to the global scientific community as both a frequent contributor to learned journals as well - and especially in the last six years - as a much sought-after speaker on the international conference circuit.
Dr. Gabibov graduated from Moscow State University in 1977, where he studied Chemical Enzymology. He currently holds several senior positions in the Biochemistry sphere in both Russia and France.
Professor Franco Cavalli M.D., F.R.C.P.
Franco Cavalli, born in 1942, was the Scientific Director of the Oncology Institute of Southern Switzerland (IOSI) in Bellinzona (Switzerland) until 2017. He created this institute, which encompasses medical oncology, radio-oncology, nuclear medicine, palliative care, hematology and an important research division. He is currently still President of the Foundation, which manages the Institute of Oncology Research (IOR), located in Bellinzona (Switzerland). He is Professor (Titular professor) of medical oncology at the Medical Faculty in Bern (Switzerland). He has an international reputation for the treatment of and research into malignant lymphoma and new drugs. Every second year he organizes in Lugano the International Conference on Malignant Lymphoma, which is the most important congress on this topic worldwide. He has been very active also in the field of the clinical evaluation of new cancer drugs. The quality of his work has been recognized by the award of 24 national and international prices, including the Petzcoller Award for special dedication to oncology and the ESMO Lifetime Achievement Award. He has published more than 600 articles in peer-reviewed journals and has contributed to many books on cancer, including the Textbook of Medical Oncology, which he edited together with S. Kaye (London), H.H. Hansen (Copenhagen) and D. Armitage (Omaha, Nebraska).
He was Founding Editor and Editor-in-Chief of Annals of Oncology, Europe’s premier medical oncology journal, from 1990 to 2000, and he is on the Editorial Board of several other journals. In 1996, he founded the International Extranodal Lymphoma Study Group (IELSG, www.ielsg.org), which encompasses now more than 200 institutions in 4 continents. IELSG is the leading cooperative group in the field of the biological and clinical studies in the field of extranodal lymphomas.
Franco Cavalli has been President of the Swiss Cancer League and is Chairman of the Scientific Committee of the European School of Oncology (ESO) and of the World Oncology Forum (WOF). He was President of the International Union Against Cancer (UICC) between 2006 and 2008. He has been member of WHO committee of selection of essential medicines for cancers since 2015.
He was member of the Swiss Parliament between 1995 and 2007.
Davide Rossi, Ph.D.
Dr. Davide Rossi obtained the specialization in Internal Medicine and his Ph.D. in Clinical and Experimental Medicine at the University of Eastern Piedmont in Novara. Dr. Rossi served as Professor of Hematology and member of the Faculty of the School of Medicine of the University of Eastern Piedmont until 2015. In 2015, Dr. Rossi moved to Switzerland where he is Deputy Head of the Division of Hematology at the Oncology Institute of Southern Switzerland (IOSI), the head of the Experimental Hematology research program at the Institute of Oncology Research (IOR), and the co-chair of the Clinical Lymphoid Tumors Investigation Program (CLIP) of the Oncology Institute of Southern Switzerland (IOSI)
Dr. Rossi’s translational research focuses on lymphomas and chronic lymphocytic leukemia and resulted in more than 250 publications on international peer-reviewed journals (total impact factor: 1678; sum of citations: 14571; H index: 65). Dr. Rossi is also the principal investigator of national and international clinical trials in the field of chronic lymphocytic leukemia.
Dr. Rossi’s research is well-recognized and highly regarded within the national and international scenario, due to his contribution to the development of chronic lymphocytic leukemia guidelines and his participation as author of the 2016 WHO Classification of Hematologic Malignancies. Dr. Rossi is regularly invited to give lectures at international meetings, to review grants for national and international funding agencies, and to review manuscripts for high impact medical journals including The Lancet and The New England Journal of Medicine.
Dr. Rossi is currently serving as Associate Editor of Haematologica (the official Journal of the European Hematology Association), as Editorial Board Member of Blood (the official Journal of the American Society of Hematology), as Member of the Scientific Program Committee Advisory Board of the Congress of the European Hematology Association, and as Member of the Organizing Committee of the International Conference on Malignant Lymphoma.
Dr. Rossi’s research activity is funded by a number of successful competitive grants, including grants from the European Research Council, the Swiss National Fund, Oncosuisse, and other national and international funding agencies.
Guenther Koehne, M.D., Ph.D.
Dr. Guenther Koehne is an internationally recognized cancer specialist and current Deputy Director and Chief of Blood & Marrow Transplant and Hematologic Oncology at the Miami Cancer Institute. He has over 30 years of extensive experience in the treatment of leukemia, myelodysplastic syndrome, multiple myeloma and other lymphoproliferative diseases, including with autologous and allogeneic stem cell transplantations. Over the course of his career, he has established a noteworthy reputation for his work in adoptive immunotherapeutic approaches with antigen-specific, donor-derived T lymphocytes in the treatment of viral complications following allogeneic transplants and has developed new approaches to the treatment of patients with high-risk multiple myeloma, minimal residual disease of leukemia and relapsed disease post-allogeneic bone marrow transplantation.
Prior to joining the Miami Cancer Institute, Dr. Koehne served as both the Assistant Professor of Medicine and Associate Professor of Medicine at Weill Cornell Medicine. Prior to that, Dr. Koehne spent over 20 years at the Memorial Sloan Kettering Cancer Center (MSKCC) and held a multitude of roles, including Medical Director of the Cytotherapy Laboratory (Bone Marrow Transplantation Laboratory) and Hematologic Oncologist. While serving as the Medical Director at MSKCC, he established new T cell depletion techniques and other methods to manipulate donor stem cell products that optimize patient outcomes.
Dr. Koehne has served as Principle Investigator or Principal Co-Investigator for a number of clinical trials involving bone marrow transplantation, particularly in the area of multiple myeloma, to study the effectiveness of T cell-depleted transplants from related and unrelated donors in patients with high-risk and relapsed multiple myeloma. He is regarded in the medical community as a pioneer in developing specific donor-derived immune cells (T lymphocytes) to treat both the viral complications of transplantation and disease relapse following transplantation. His developed treatment approach is a type of adoptive immunotherapy, and is being administered in several active clinical trials.
A physician-scientist, Dr. Koehne received his M.D. and Ph.D. from Medical University of Hamburg, Germany. He completed his residency in Internal Medicine at Medical University of Hamburg and Rush University Medical Center in Chicago. He completed his medical oncology/hematology fellowship at Memorial Sloan Kettering Cancer Center, and an additional research fellowship in the Immunology Program at the Sloan Kettering Institute for Cancer Research, Allogeneic Bone Marrow Transplantation Service, where he also served as a research associate.